All In Biotech

Drug Trial Radar · NCT03891576

Newton Study (NEW Dosing MainTenance Therapy Ovarian CaNcer)

A Multicenter, Open-label Phase II Trial of a New Customized Dosing (RADAR Dosing) of Niraparib As Maintenance Therapy in Platinum Sensitive Ovarian, Fallopian Tube or Primary Peritoneal Recurrent Cancer Patients

Last checked: Nov 20, 2026Latest source record: Jan 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

83

Actual

Start

Nov 13, 2019

Primary completion

Aug 31, 2024

Study completion Aug 31, 2024

Sponsor

Lead sponsor
Mario Negri Institute for Pharmacological ResearchAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
North Eastern German Society of Gynaecological Oncology
First posted
Mar 27, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study evaluates whether the adoption of the RADAR dosing strategy could further reduce treatment related toxicities improving the safety profile of niraparib.

Conditions

  • Ovarian Cancer
  • Fallopian Tube Cancer
  • Primary Peritoneal Carcinoma

Interventions

  • NiraparibDrug

    Niraparib is a potent, orally active PARP1 and PARP2 inhibitor being developed as a treatment for patients with tumors that harbor defects in the homologous recombination DNA repair pathway or that are driven by PARP-mediated transcription factors.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety: Occurrence of grade ≥3 thrombocytopeniaTime frame: 3 months

Locations

12 sites in 2 countries. Site status is shown where the registry gives one.

  • Charité - Universitätsmedizin Berlin

    Berlin, Germany

  • University Hospital Dresden

    Dresden, Germany

  • Kliniken Essen Mitte

    Essen, Germany

  • ASST degli Spedali Civili di Brescia

    Brescia, Italy

  • Istituto Europeo di Oncologia

    Milan, Italy

  • Istituto Nazionale dei Tumori

    Milan, Italy

  • Ospedale San Gerardo

    Monza, Italy

  • Istituto Oncologico Veneto (IOV)

    Padova, Italy

  • AO Arcispedale Santa Maria Nuova

    Reggio Emilia, Italy

  • Policlinico Umberto I, Università di Roma "La Sapienza"

    Roma, Italy

  • AO Ordine Mauriziano

    Torino, Italy

  • AOU Città della Salute e della Scienza di Torino - Ospedale Sant'Anna

    Torino, Italy

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.